These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

407 related items for PubMed ID: 15374950

  • 21. Simultaneous treatment with benzyl isothiocyanate, a strong bladder promoter, inhibits rat urinary bladder carcinogenesis by N-butyl-N-(4-hydroxybutyl)nitrosamine.
    Okazaki K, Yamagishi M, Son HY, Imazawa T, Furukawa F, Nakamura H, Nishikawa A, Masegi T, Hirose M.
    Nutr Cancer; 2002; 42(2):211-6. PubMed ID: 12416262
    [Abstract] [Full Text] [Related]

  • 22. Development of an experimental model for studying bladder carcinogen metabolism using the isolated rat urinary bladder.
    Airoldi L, Bonfanti M, Magagnotti C, Fanelli R.
    Cancer Res; 1987 Jul 15; 47(14):3697-700. PubMed ID: 3594434
    [Abstract] [Full Text] [Related]

  • 23. Induction of NAD(P)H quinone: oxidoreductase1 inhibits carcinogen-induced aberrant crypt foci in colons of Sprague-Dawley rats.
    Begleiter A, Sivananthan K, Curphey TJ, Bird RP.
    Cancer Epidemiol Biomarkers Prev; 2003 Jun 15; 12(6):566-72. PubMed ID: 12815004
    [Abstract] [Full Text] [Related]

  • 24. Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis.
    Izumi K, Zheng Y, Hsu JW, Chang C, Miyamoto H.
    Mol Carcinog; 2013 Feb 15; 52(2):94-102. PubMed ID: 22086872
    [Abstract] [Full Text] [Related]

  • 25. Chemoprotection by organosulfur inducers of phase 2 enzymes: dithiolethiones and dithiins.
    Kensler TW, Curphey TJ, Maxiutenko Y, Roebuck BD.
    Drug Metabol Drug Interact; 2000 Feb 15; 17(1-4):3-22. PubMed ID: 11201301
    [Abstract] [Full Text] [Related]

  • 26. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder.
    Rao KV, Detrisac CJ, Steele VE, Hawk ET, Kelloff GJ, McCormick DL.
    Carcinogenesis; 1996 Jul 15; 17(7):1435-8. PubMed ID: 8706245
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The impact of glucuronidation on the bioactivation and DNA adduction of the cooked-food carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in vivo.
    Malfatti MA, Ubick EA, Felton JS.
    Carcinogenesis; 2005 Nov 15; 26(11):2019-28. PubMed ID: 15944213
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Tissue-specific mutagenesis by N-butyl-N-(4-hydroxybutyl)nitrosamine as the basis for urothelial carcinogenesis.
    He Z, Kosinska W, Zhao ZL, Wu XR, Guttenplan JB.
    Mutat Res; 2012 Feb 18; 742(1-2):92-5. PubMed ID: 22155125
    [Abstract] [Full Text] [Related]

  • 31. Lack of preventive efficacy of FK228, a histone deacetylase inhibitor, against N-butyl-N-(4-hydroxybutyl) nitrosamine-induced urinary bladder carcinogenesis in p53+/- and p53+/+ mice.
    Wei M, Wanibuchi H, Morimura K, Salim EI, Moku M, Doi K, Mitsuhashi M, Masuda C, Shen J, Kinoshita A, Fukushima S.
    Anticancer Res; 2004 Feb 18; 24(2B):785-90. PubMed ID: 15161027
    [Abstract] [Full Text] [Related]

  • 32. Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice.
    Tyagi A, Raina K, Singh RP, Gu M, Agarwal C, Harrison G, Glode LM, Agarwal R.
    Mol Cancer Ther; 2007 Dec 18; 6(12 Pt 1):3248-55. PubMed ID: 18089718
    [Abstract] [Full Text] [Related]

  • 33. Inhibitory effect of 13-cis-retinoic acid on urinary bladder carcinogenesis induced in C57BL/6 mice by N-butyl-N-(4-hydroxybutyl)-nitrosamine.
    Becci PJ, Thompson HJ, Grubbs CJ, Squire RA, Brown CC, Sporn MB, Moon RC.
    Cancer Res; 1978 Dec 18; 38(12):4463-6. PubMed ID: 719631
    [Abstract] [Full Text] [Related]

  • 34. Susceptibility of p27 kip1 knockout mice to urinary bladder carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine may not simply be due to enhanced proliferation.
    Hikosaka A, Ogawa K, Sugiura S, Asamoto M, Takeshita F, Sato SY, Nakanishi M, Kohri K, Shirai T.
    Int J Cancer; 2008 Mar 15; 122(6):1222-8. PubMed ID: 18027869
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The interaction of arsenic and N-butyl-N-(4-hydroxybutyl)nitrosamine on urothelial carcinogenesis in mice.
    Dai YC, Wang SC, Haque MM, Lin WH, Lin LC, Chen CH, Liu YW.
    PLoS One; 2017 Mar 15; 12(10):e0186214. PubMed ID: 29016672
    [Abstract] [Full Text] [Related]

  • 38. Chemoprevention of mouse urinary bladder carcinogenesis by the naturally occurring carotenoid astaxanthin.
    Tanaka T, Morishita Y, Suzui M, Kojima T, Okumura A, Mori H.
    Carcinogenesis; 1994 Jan 15; 15(1):15-9. PubMed ID: 8293542
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Role of hepatitis B virus X repression of C/EBPbeta activity in the down-regulation of glutathione S-transferase A2 gene: implications in other phase II detoxifying enzyme expression.
    Cho IJ, Ki SH, Brooks C, Kim SG.
    Xenobiotica; 2009 Feb 15; 39(2):182-92. PubMed ID: 19255944
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.